XML 73 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities
12 Months Ended
Dec. 31, 2014
Available-for-sale Securities [Abstract]  
Marketable Securities
Marketable Securities
Rambus invests its excess cash and cash equivalents primarily in U.S. government sponsored obligations, commercial paper, corporate notes and bonds, money market funds and municipal notes and bonds that mature within three years. As of December 31, 2014 and 2013, all of the Company’s cash equivalents and marketable securities have a remaining maturity of less than one year.
All cash equivalents and marketable securities are classified as available-for-sale. Total cash, cash equivalents and marketable securities are summarized as follows:
 
As of December 31, 2014
(Dollars in thousands)
Fair Value
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Weighted Rate of Return
Money market funds
$
124,938

 
$
124,938

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
145,983

 
146,096

 
1

 
(114)

 
0.25
%
Total cash equivalents and marketable securities
270,921

 
271,034

 
1

 
(114)

 
 
Cash
29,188

 
29,188

 

 

 
 
Total cash, cash equivalents and marketable securities
$
300,109

 
$
300,222

 
$
1

 
$
(114
)
 
 
 
As of December 31, 2013
(Dollars in thousands)
Fair Value
 
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Weighted Rate of Return
Money market funds
$
300,605

 
$
300,605

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
58,492

 
58,507

 

 
(15
)
 
0.15
%
Total cash equivalents and marketable securities
359,097

 
359,112

 

 
(15
)
 
 
Cash
28,565

 
28,565

 

 

 
 
Total cash, cash equivalents and marketable securities
$
387,662

 
$
387,677

 
$

 
$
(15
)
 
 

Available-for-sale securities are reported at fair value on the balance sheets and classified as follows:
 
As of
 
December 31,
2014
 
December 31,
2013
 
(Dollars in thousands)
Cash equivalents
$
124,938

 
$
310,131

Short term marketable securities
145,983

 
48,966

Total cash equivalents and marketable securities
270,921

 
359,097

Cash
29,188

 
28,565

Total cash, cash equivalents and marketable securities
$
300,109

 
$
387,662


The Company continues to invest in highly rated quality, highly liquid debt securities. As of December 31, 2014, these securities have a remaining maturity of less than one year. The Company holds all of its marketable securities as available-for-sale, marks them to market, and regularly reviews its portfolio to ensure adherence to its investment policy and to monitor individual investments for risk analysis, proper valuation, and unrealized losses that may be other than temporary.
The estimated fair value of cash equivalents and marketable securities classified by the length of time that the securities have been in a continuous unrealized loss position at December 31, 2014 and 2013 are as follows:
 
Fair Value
 
Gross Unrealized Loss
 
December 31,
2014
 
December 31,
2013
 
December 31,
2014
 
December 31,
2013
 
(In thousands)
Less than one year
 
 
 
 
 
 
 
Corporate notes, bonds and commercial paper
$
139,989

 
$
53,491

 
$
(114
)
 
$
(15
)

The gross unrealized loss at December 31, 2014 and 2013 was not material in relation to the Company’s total available-for-sale portfolio. The gross unrealized loss can be primarily attributed to a combination of market conditions as well as the demand for and duration of the corporate notes and bonds. The Company has no intent to sell, there is no requirement to sell and the Company believes that it can recover the amortized cost of these investments. The Company has found no evidence of impairment due to credit losses in its portfolio. Therefore, these unrealized losses were recorded in other comprehensive income (loss). However, the Company cannot provide any assurance that its portfolio of cash, cash equivalents and marketable securities will not be impacted by adverse conditions in the financial markets, which may require the Company in the future to record an impairment charge for credit losses which could adversely impact its financial results.
See Note 9, “Fair Value of Financial Instruments,” for discussion regarding the fair value of the Company’s cash equivalents and marketable securities.